FDA Approves Nilotinib for Paediatric patients with Newly Diagnosed or Resistant/Intolerant Ph-Positive CML in Chronic Phase

2018-03-28 22:16:00

Approval is based on results in paediatric patients from CAMN107A2120 and CAMN107A2203 studies

Source

Oncology Breast CNS Chemotherapy Endocrine GI GU Geriatric Gynecologic GYN-OB Head and Neck Haematology Immunotherapy Lung Melanoma Skin NET Paediatric Pathology Sarcoma Surgery Targeted Therapy Translational
  • Save
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply